The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
2020 · Blood · 327 citations
https://doi.org/10.1182/blood.2020006288
A
Alan P Skarbnik
Novant Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
195
Papers
4.4K
Citations
27
h-index
57
i10-index
Alan P Skarbnik is an academic researcher from Novant Health. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Advanced Breast Cancer Therapies. The author has an h-index of 27, co-authored 166 publications.
ORCID: 0000-0002-1276-7546Papers by this author
worksEfficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
2022 · Leukemia · 194 citations
https://doi.org/10.1038/s41375-021-01485-x
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 · New England Journal of Medicine · 76 citations
https://doi.org/10.1056/nejmoa2409804
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
2019 · Blood · 61 citations
https://doi.org/10.1182/blood-2019-128404
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
2024 · The Lancet Oncology · 33 citations
https://doi.org/10.1016/s1470-2045(24)00070-6
CLL-495 Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01287-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat